Finasteride vs. Spironolactone for Hair Loss

Finasteride and spironolactone are both anti-androgenic agents used for hair loss, but they target different points in the androgen pathway and are used in very different patient populations. Finasteride is FDA-approved for men. Spironolactone is most commonly used off-label for women with female pattern hair loss (FPHL) and hyperandrogenism. Direct comparison is therefore mostly relevant to the specific niche where both are considered: premenopausal women with FPHL.

Mechanism Comparison

	Finasteride	Spironolactone
Drug class	5-alpha-reductase inhibitor (Type II)	Aldosterone antagonist; androgen receptor antagonist
Mechanism in hair loss	Reduces DHT production; removes androgenic stimulus from follicle	Blocks androgen receptor; also reduces androgen production at higher doses
FDA approval for AGA	Men only (1997)	Not approved for AGA (approved for hypertension, heart failure, hyperaldosteronism)
Use in men	Yes — standard first-line	Not appropriate for AGA in men (causes feminizing effects — gynecomastia, sexual dysfunction at anti-androgenic doses)
Use in women	Off-label; Pregnancy Category X contraindication	Off-label for FPHL; Category C/D — not in pregnancy
Evidence for FPHL	Positive only at 2.5 mg+ in postmenopausal women with hyperandrogenism	Positive observational data; multiple small positive trials; no large RCT
Typical dose for FPHL	2.5–5 mg/day (off-label)	50–200 mg/day

Who Gets Which?

Patient	Typical choice
Men with AGA	Finasteride 1 mg (FDA-approved); minoxidil as add-on
Postmenopausal women with FPHL	Finasteride 2.5 mg or spironolactone 50–200 mg; both off-label
Premenopausal women with FPHL and normal androgens	Minoxidil (FDA-approved); spironolactone considered by some dermatologists
Premenopausal women with FPHL and hyperandrogenism	Spironolactone (most commonly used); finasteride less preferred due to Pregnancy Category X

Why Spironolactone Is Preferred for Premenopausal Women

Finasteride is Pregnancy Category X — absolutely contraindicated in pregnancy. In premenopausal women, even with contraception, this represents a substantial absolute risk concern. Spironolactone is Category C/D (not recommended in pregnancy), but has a longer history of use in premenopausal women with FPHL and hyperandrogenism. Effective contraception is required with both drugs in women of childbearing potential, but the threshold for using finasteride in premenopausal women is higher given the severity of the teratogenicity risk.

For men, finasteride is the clear first-line pharmacological choice. Spironolactone is not used for male AGA because its anti-androgenic effects at therapeutic doses cause feminizing side effects (gynecomastia, breast tenderness, sexual dysfunction) that are unacceptable to most men.

See also: Finasteride for women | Finasteride alternatives